The fetal ECG: accuracy of measurements

Neurobehavioral assessment before birth

The complexities of neurobehavioral assessment of the fetus, which can be neither directly viewed nor manipulated, cannot be understated. Impetus to develop methods for measuring fetal neurobehavioral development has been provided by the recognition that individual differences in neurobehavioral functioning do not originate with birth and acceptance of the key contribution of the antenatal period to postnatal life. Research has centered around four aspects of fetal functioning: heart rate, motor activity, behavioral state, and responsivity to stimulation. Longitudinal studies have revealed that the developmental trajectories of these characteristics parallel the developing nervous system, detected a transitional period between 28 and 32 weeks gestation, and established within-fetal stability during the second half of gestation. Despite the promise of fetal stimulation and habituation paradigms as measures of neural functioning, significant safety and ethical concerns exist. Construction of a unified fetal neurobehavioral scale is premature until a sufficient degree of normative data is available and the predictive validity of specific aspects of fetal neurobehavior to child developmental outcomes is better established.

The psychophysiology of the maternal-fetal relationship

The enigmatic quality of the maternal-fetal relationship has been extolled throughout history with little empirical support. We apply time series analysis to data for 137 maternal-fetal pairs collected at 20, 24, 28, 32, 36, and 38 weeks gestation. Maternal heart rate and skin conductance data were digitized in tandem with fetal heart rate and motor activity. No temporal relations between fetal heart rate and either maternal variable were found, although averaged maternal and fetal heart rates were correlated from 32 weeks. Consistent temporal associations between fetal movement and maternal heart rate and skin conductance were detected. Fetal movement stimulated rises in each parameter, peaking at 2 and 3 s, respectively. Associations did not change over gestation, were unaffected by a maternal stressor, and showed within-pair stability. The bidirectional nature of the maternal-fetal relationship is considered.

Power spectral analysis of fetal heart rate

This chapter examines the role of power spectral analysis (PSA) in elucidation of the physiological control mechanisms of fetal heart rate and as a potential indicator of fetal well-being. The importance of fetal heart rate variability (FHRV) as an indicator of fetal oxygenation is discussed, and the limitations in the current methods of measurement of FHRV are highlighted. Evidence is presented for the paramount influence of the autonomic nervous system in the control of heart rate variability. The basic proposition underlying spectral analysis is that the two autonomic branches influence heart rate in a frequency-dependent way, and their differential effects can be determined by PSA which breaks down the heart rate trace into its component frequencies. The application of PSA to heart rate variability data is an established tool in cardiology, and the published literature related to its use in the adult, neonate and fetus is reviewed. The power spectrum is sensitive to the activity state of the fetus, particularly fetal breathing movements, which have a variable effect on short- and long-term FHRV. There are a variety of mathematical approaches to the construction of power spectra, and a particular method of data acquisition and analysis is presented together with some theoretical background. Recent experimental evidence indicates a role for PSA as an indicator of fetal activity state, and the effect of hypoxia on the spectrum of the fetus in labour is discussed. There are some problems with the technique of PSA, particularly in regard to accepted definitions and methods of analysis. It is a powerful non-invasive tool in the elucidation of fetal cardiac control, but its value in the detection of the compromised fetus has yet to be tested in a clinical trial.